The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
The company will now seek final approval from NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE
ALS patients experience neuroinflammation and rapid neurodegeneration
The partnership aims to revolutionize Artificial Intelligence in health research with innovative data platform
The study observed 2,648 girls, of which 2,300 completed the standard 45-day programme
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
The study highlighted substantial improvements in key clinical parameters among RA patients who underwent AWS intervention
USFDA has determined that the inspection classification of this facility is "No Action Indicated" (NAI) with zero 483 observation
Subscribe To Our Newsletter & Stay Updated
